More Proof of the ReCODE Protocol’s Success – 2023
ReCODE™ Protocol Effectiveness
More Evidence That Early-Stage Alzheimer’s Can Be Reversed
Study: Observed Improvement in Cognition During a Personalized Lifestyle Intervention in People with Cognitive Decline – 2023
A team led by Heather Sandison, ND, conducted a clinical trial testing the efficacy of a personalized medicine protocol using a multimodal approach to treat cognitive decline in 34 participants over six months. The resulting paper, co-authored by Ram Rao, Ph.D., the Principal Research Scientist for Apollo Health, was published in the Journal of Alzheimer’s Disease. The multimodal intervention included lifestyle changes (i.e., movement, diet, and stress management), nutraceutical support, and medications. It was delivered pragmatically over four clinical visits, and outcome measures were gathered at four study visits, occurring at baseline, one, three, and six months (primary endpoint). Results showed significant improvements in overall cognition and memory based on Cambridge Brain Sciences assessments and increased scores in the Montreal Cognitive Assessment. More than half of the participants demonstrated improvement in various cognitive domains. The study provides evidence for the potential efficacy of individualized interventions in addressing cognitive decline. For more information, read the full paper here.
This article, published in the International Journal of Molecular Sciences, was authored by Apollo Health’s Ram Rao, Ph.D., Julie Gregory, Christine Coward, Sho Okada, Lance Kelly, Dale Bredesen, M.D., Aida Lasheen Bredesen, M.D., and Kaavya Subramaniam. Recent dementia and Alzheimer’s research highlights diverse contributors like diet, lifestyle, stress, sleep, and toxins, endorsing lifestyle changes to impede AD. Studies advocate a personalized, multi-pronged strategy to address metabolic anomalies and cognitive decline, pinpointing factors such as insulin resistance, inflammation, nutrient deficiencies, and hormonal imbalances. This review underscores the necessity of a comprehensive approach that aligns with individual genetics and biochemistry, surpassing single-drug solutions. By analyzing multiple interventions concurrently, encompassing lifestyle, physical and mental activities, and nutrition, this article underscores the intricate nature of AD. It advocates for a holistic strategy to combat its various risk factors, surpassing the limitations of monotherapy. Learn more here.
This analysis was led by our Principal Research Scientist, Ram Rao, Ph.D. and co-authored by Apollo Health’s Julie Gregory, Christine Coward, Sho Okada, William Lipa, Lance Kelly, Dale Bredesen, M.D., and voluntary data scientist Sharanya Kumar. Using Apollo Health’s personalized therapeutic system, the ReCODE™ Program, which proved successful in a small, proof-of-concept trial, our team sought to determine whether this program could be scaled to improve cognitive and metabolic function in individuals diagnosed with subjective cognitive impairment, mild cognitive impairment, and early-stage AD. By comparing baseline to follow-up testing of 255 ReCODE participants, it was observed that MoCA scores either significantly improved or stabilized in the entire participant pool, and other risk factors, including blood glucose, high-sensitivity C-reactive protein, HOMA-IR, and vitamin D also improved in the participant pool. Our findings prove that a multi-factorial, comprehensive, and personalized therapeutic program designed to mitigate AD risk factors can improve risk factor scores and stabilize or reverse the decline in cognitive function. Learn more here.
The Bredesen Protocol® is based on over three decades of Dr. Bredesen’s laboratory research, resulting in hundreds of peer-reviewed publications that have uncovered the biochemical mechanisms behind the erosion of memory associated with Alzheimer’s disease. For anyone who would like to learn more about Dr. Bredesen’s science, click on the button below.
We support physicians, other medical professionals, lifestyle, and nutrition experts by providing dynamic, evolving solutions for cognitive decline, empowering practitioners both to prevent and reverse symptoms. Practitioners who are interested in learning how to use the Bredesen Protocol, click on the button below.
Apollo Health is building the first-ever brain health community around the prevention and reversal of cognitive decline, providing you with the resources to build the care team you need, which might consist of a lead physician, a health coach, a nutritionist, and your choice of many additional specialists with all of the tools and resources necessary for success. For anyone interested in learning more about the Bredesen Protocol, click on the button below.